An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.
Status:
Terminated
Trial end date:
2019-11-19
Target enrollment:
Participant gender:
Summary
This study evaluated the safety and tolerability of LCZ696 treatment in Japanese heart
failure patients (NYHA Class II-IV) with preserved ejection fraction after CLCZ696D2301
(PARAGON-HF).
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan